Individualized Blood Pressure Management in Patients Undergoing Cardiac Surgery (PRECISE)
Individualized Blood Pressure Management in Patients Undergoing Cardiac Surgery. A Pilot, Randomized Controlled Study
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Adequate hemodynamic control is a cornerstone in management in patients undergoing different types of surgery. Among all perioperative risk factors, the association between perioperative hypotension and adverse clinical outcomes in noncardiac and cardiac surgery patients is well defined.
Numerous factors are responsible for development of perioperative hypotension. They include but not limited to perioperative use of renin-angiotensin-aldosterone system and calcium channel blockers, hypovolemia, hemodilution, bleeding and inflammatory response syndrome.
To date, several evidence has been accumulated indicating that intraoperational hypertension can be hazardous.
It was shown that even short durations (1 to 5 min) of an intraoperative mean arterial pressure < 55 mmHg were associated with myocardial injuries and acute kidney injury (AKI).
Results of recent large retrospective cohort study conducted in adult patients who underwent cardiac surgery requiring CPB showed that postoperative stroke was strongly associated with sustained mean arterial pressure of less than 64 mmHg during cardiopulmonary bypass.
In patients undergoing CABG the overall incidence of combined cardiac and neurologic complications was significantly lower in the group where MAP during CPB was relatively high (80-110 mmHg) than in the low pressure group (MAP 50-60 mmHg) (p = 0.026). For each of the individual outcomes the trend favored the high pressure group.
Therefore, MAP may be an important intraoperative therapeutic hemodynamic target to reduce the incidence of complications in patients undergoing CPB.
Tipo de estudo
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Novosibirsk, Federação Russa, 630055
- Meshalkin Research Institute of Pathology of Circulation
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- ≥18 years old
- Signed informed consent
- Elective cardiac surgery under CPB (CABG or valve surgery)
Exclusion Criteria:
- Unstable Coronary Artery Disease: Recent (< 6 weeks) myocardial infarction, unstable angina, severe (> 70%) left main coronary artery stenosis
- Uncontrolled hypertension preoperatively (SBP > 160 mm Hg)
- Critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or intraaortic balloon pumping, preoperative severe acute renal failure (anuria or oliguria <10ml/hr)
- Planned surgery on aorta
- Emergency surgery
- Pregnancy
- Current enrollment into another randomized controlled trial (in the last 30 days)
- Previous enrollment and randomization into current study
- Glomerular filtration rate ≤59 ml/min/1.73m2 (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Individualized BP group
Individualized intraoperative BP management
|
In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP). Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status. |
|
Comparador de Placebo: Standard treatment group
Standard intraoperative BP management
|
Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg.
MAP during CPB will be maintained at 50-60 mm Hg.
If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started.
No vasodilators will be used if MAP will exceed predefined range.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Compliance with the protocol
Prazo: Operative day 1
|
Successful compliance with protocol is defined as ≥ 90% of prescribed intervention being administered across all patients.
|
Operative day 1
|
|
Successful recruitment rate
Prazo: 12 month
|
Successful recruitment rate will be defined as recruitment of 2 patients per week.
|
12 month
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative creatinine concentration
Prazo: 3 days after surgery
|
Plasma creatinine level will be measured daily during 3 postoperative days.
|
3 days after surgery
|
|
Postoperative cardiac troponin I level
Prazo: 12 hours after surgery
|
Cardiac troponin I level wil be measured in the time frame from 6 to 12 hours postoperatively.
|
12 hours after surgery
|
|
Intraoperative blood pressure
Prazo: Operative day 1
|
Intraoperative blood pressure (mean, systolic and diastolic) will be registered every 5 minutes intraoperatively using invasive blood pressure monitoring system.
|
Operative day 1
|
|
Rate of postoperative complications
Prazo: 30 days after surgery
|
Postoperative complications (myocardial infarction, atrial fibrillation, stroke, delirium, need for renal replacement therapy, infection, reexploration for bleeding) will be defined according to standard European Society of Anaesthesiology/European Society of Intensive Care Medicine definitions where possible.
|
30 days after surgery
|
|
Postoperative blood loss
Prazo: Postoperative day 1
|
Drainage volume (ml/kg) will be measured in the next morning after surgery.
|
Postoperative day 1
|
|
Daily Sequential Organ Failure Assessment (SOFA) score
Prazo: 30 days after surgery
|
Organ failure will be assessed by using Sequential Organ Failure Assessment (SOFA) score which will be recorded daily until patient discharge from the ICU.
The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.
Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure).
The score ranges from 0 to 24 points (the higher the score, the higher the mortality).
|
30 days after surgery
|
|
Peak concentration of lactate during CPB and up to 24 hours after surgery
Prazo: Postoperative day 1
|
Lactate values (mmol/l) will be measured every 6 hours during the first 24 postoperative hours.
|
Postoperative day 1
|
|
Oxygen delivery during CPB
Prazo: Operative day 1
|
Oxygen delivery during CPB will be calculated according to the standard formula (pump flow x O2 arterial content).
|
Operative day 1
|
|
Cerebral oxygenation (near infrared spectroscopy)
Prazo: Operative day1
|
Number of cerebral desaturations will be recorded intraoperatively.
|
Operative day1
|
|
Ventilation > 24 hours
Prazo: 30 days after surgery
|
Number of patients with duration of ventilation more than 24 h.
|
30 days after surgery
|
|
Duration of ICU stay and hospitalization
Prazo: 30 days after surgery
|
Number of postoperative days spent in the ICU and in the hospital will be counted.
|
30 days after surgery
|
|
30-day all-cause mortality
Prazo: 30 days after surgery
|
Number of patients who will die within 30-day after surgery from any cause
|
30 days after surgery
|
|
Need for blood transfusions
Prazo: 30 days after surgery
|
Number of patients who will need transfusions of any blood products (RBC, fresh frozen plasma, platelets, cryoprecipitate).
|
30 days after surgery
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Vladimir Lomivorotov, MD, PhD, Meshalkin Research Institute of Pathology of Circulation
Publicações e links úteis
Publicações Gerais
- Sun LY, Chung AM, Farkouh ME, van Diepen S, Weinberger J, Bourke M, Ruel M. Defining an Intraoperative Hypotension Threshold in Association with Stroke in Cardiac Surgery. Anesthesiology. 2018 Sep;129(3):440-447. doi: 10.1097/ALN.0000000000002298. Erratum In: Anesthesiology. 2019 Feb;130(2):360.
- Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26.
- Bijker JB, van Klei WA, Vergouwe Y, Eleveld DJ, van Wolfswinkel L, Moons KG, Kalkman CJ. Intraoperative hypotension and 1-year mortality after noncardiac surgery. Anesthesiology. 2009 Dec;111(6):1217-26. doi: 10.1097/ALN.0b013e3181c14930.
- Monk TG, Saini V, Weldon BC, Sigl JC. Anesthetic management and one-year mortality after noncardiac surgery. Anesth Analg. 2005 Jan;100(1):4-10. doi: 10.1213/01.ANE.0000147519.82841.5E.
- Sessler DI, Khanna AK. Perioperative myocardial injury and the contribution of hypotension. Intensive Care Med. 2018 Jun;44(6):811-822. doi: 10.1007/s00134-018-5224-7. Epub 2018 Jun 4.
- Gold JP, Charlson ME, Williams-Russo P, Szatrowski TP, Peterson JC, Pirraglia PA, Hartman GS, Yao FS, Hollenberg JP, Barbut D, et al. Improvement of outcomes after coronary artery bypass. A randomized trial comparing intraoperative high versus low mean arterial pressure. J Thorac Cardiovasc Surg. 1995 Nov;110(5):1302-11; discussion 1311-4. doi: 10.1016/S0022-5223(95)70053-6.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 19
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .